Pharma and medtech companies operating in Australia have just over three weeks to comment on draft Australian guidance on how to choose the most appropriate regulatory pathway for products that do not clearly fit within the existing definitions for medicines, biologicals or medical devices.
The new guidance, which has been drafted by the Therapeutic Goods Administration, is intended to replace the existing guideline...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?